Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

enVVeno Medical Q3 2026 Results: Net Loss of $4.37M, Loss Narrows

enVVeno Medical Corp reported a net loss of $11.8 million for the first nine months of 2026, an improvement from the $15.7 million loss in the prior year period. The company is transitioning into a pivotal U.S. clinical study for its enVVe System after receiving FDA IDE approval in April 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-4.4-4.5
EPS (diluted, $ a share)$-6.29$-7.89

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: NVNO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

enVVeno Medical Corp: key numbers

Share price
$5.95Close, Nov 16
Market cap
$4.13M
Shares outstanding
694.83KLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.